Clinical Trial Search

Primary: Evaluation of Platelet Inhibition — 94; 141 P2Y12 Reaction Units (PRU)

Primary: Clinical Cure (Complete Resolution of Signs and Symptoms) — 119; 37; 69; 47 Participants

Primary: Clinical Cure (Complete Resolution of Signs and Symptoms) — 95; 28; 93; 70 Participants

Primary: Number and Percentage of Subjects With Successful Bowel Cleansing — 257; 241 Participants — p=<0.001

Primary: Mortality — 93; 61; 52; 84 deaths

Primary: Number and Percentage of Subjects With Successful Bowel Cleansing — 175; 174 Participants — p=<0.001

Primary: Post-operative Pain Intensity — 4.7482; 5.03; 5.75; 6.64 score on a scale

Primary: Percentage of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs — 77.8 percentage of participants

Primary: Percentage of Participants With a Protective Hepatitis B Surface Antibody Level of ≥10 Milli International Units/mL (mIU/mL) at 30 Days Post-Challenge With HBVAXPRO™…

Primary: Number of Participants With Bone Tunnel Expansion — 0; 4; 10; 6 Participants

Primary: Percentage of Participants With at Least a 70% Reduction in Fasting Serum Bile Acid (s-BA) Concentration From Baseline to the End of Treatment or Reaching a Level <=70…

Primary: Preoperative Anxiety — 27; 28 score on a scale

Primary: Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24/Baseline — 0.43; 0.43; 0.37 Ratio — p=0.875

Primary: Incidence of TEAEs (Treatment-emergent Adverse Events) — 256; 38 Treatment-Emergent Adverse Events

Primary: Percentage of Participants in Clinical Remission at 10 Weeks — 18.4; 6.0; 21.0 Percentage — p=0.0001